Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion type Assertion NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_head.
- NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion description "[Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_provenance.
- NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion evidence source_evidence_literature NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_provenance.
- NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion SIO_000772 24687382 NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_provenance.
- NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion wasDerivedFrom befree-2016 NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_provenance.
- NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_assertion wasGeneratedBy ECO_0000203 NP1169077.RAUVBnfbr20a_wIcMAfglYLa9-n7QZL542fJJEanhDYNI130_provenance.